Blau Farmacêutica S.A. Stock: price and insider trades · Brazil
Blau Farmacêutica S.A.: what insiders have been doing
This page follows insider dealings at Blau Farmacêutica S.A. as filed with CVM (Brazil), a company from the Health Care sector. In the past year (4 November 2025 to 4 November 2026), 3 filings came from 2 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Insider buying of Blau Farmacêutica S.A. has been absent for the past year. The median gap between a trade and its publication by CVM (Brazil) is 38 days. The shorter that gap, the sooner other investors can see what insiders have done.
Across the 343 companies tracked on its exchange, the median is 23 filings; at 3 filings, this issuer sits below that mark. Since 2021, the database holds 30 purchases and 3 sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Source: insider filings from CVM (Brazil). Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
- 44,399,999 shares@ R$7.4324100.0% of flowAçõesB3CVM:58430828-3c92e0e1d1903bc1
- 600 shares@ R$7.43170.3% of flowAçõesB3CVM:58430828-1af09cae9602f3ba
- 7,364 shares@ R$7.43244.0% of flowAçõesB3CVM:58430828-c711f8aec565e68c
- 1,000 shares@ R$31.302.9% of flowAçõesB3CVM:58430828-e02556a4be12ad4aCanonical exit: 24 Nov 2022 (T+90)
- 500 shares@ R$31.451.5% of flowAçõesB3CVM:58430828-c1547224045167aeCanonical exit: 23 Nov 2022 (T+90)
- 900 shares@ R$31.302.6% of flowAçõesB3CVM:58430828-d1dd243e80e3e94aCanonical exit: 24 Nov 2022 (T+90)
- 200 shares@ R$31.800.6% of flowAçõesB3CVM:58430828-4ac18a6efcbd58f5Canonical exit: 27 Nov 2022 (T+90)
- 300 shares@ R$31.700.9% of flowAçõesB3CVM:58430828-383fbce305a076a7Canonical exit: 27 Nov 2022 (T+90)
- 100 shares@ R$31.280.3% of flowAçõesB3CVM:58430828-7315e56f35382a1b
- 300 shares@ R$31.270.9% of flowAçõesB3CVM:58430828-8fb4109070910365
- 1,000 shares@ R$31.252.9% of flowAçõesB3CVM:58430828-92e3dfd35212e5da
- 500 shares@ R$31.601.5% of flowAçõesB3CVM:58430828-4e9f6e1cf063de28Canonical exit: 23 Nov 2022 (T+90)
- 500 shares@ R$31.401.5% of flowAçõesB3CVM:58430828-516e419b61e255e7Canonical exit: 23 Nov 2022 (T+90)
- 300 shares@ R$31.400.9% of flowAçõesB3CVM:58430828-2af6198069f04cc5Canonical exit: 24 Nov 2022 (T+90)
- 200 shares@ R$31.350.6% of flowAçõesB3CVM:58430828-11f8f80a99199d68Canonical exit: 24 Nov 2022 (T+90)
- 500 shares@ R$31.351.5% of flowAçõesB3CVM:58430828-cce59640b67c6e6bCanonical exit: 24 Nov 2022 (T+90)
- 700 shares@ R$31.402.1% of flowAçõesB3CVM:58430828-4cf3855ad1edc648Canonical exit: 24 Nov 2022 (T+90)
- 300 shares@ R$40.452.9% of flowAçõesB3CVM:58430828-51e5203127d8c5a6Canonical exit: 4 Jan 2022 (T+90)
- 200 shares@ R$39.551.8% of flowAçõesB3CVM:58430828-1a873f0f197a9328Canonical exit: 9 Jan 2022 (T+90)
- 200 shares@ R$39.581.9% of flowAçõesB3CVM:58430828-80d91f03bb266494Canonical exit: 9 Jan 2022 (T+90)
- 100 shares@ R$51.001.2% of flowAçõesB3CVM:58430828-fb0085a2564a5e77Canonical exit: 30 Nov 2021 (T+90)
- 200 shares@ R$45.352.2% of flowAçõesB3CVM:58430828-7a77a5caf02b5cceCanonical exit: 28 Dec 2021 (T+90)
- 200 shares@ R$46.502.2% of flowAçõesB3CVM:58430828-d7811e373b7f3121Canonical exit: 19 Dec 2021 (T+90)
- 600 shares@ R$51.007.4% of flowAçõesB3CVM:58430828-ff52066f4b220e20Canonical exit: 30 Nov 2021 (T+90)
- 2,000 shares@ R$49.077.6% of flowAçõesB3CVM:58430828-76408358b7935370Canonical exit: 15 Dec 2021 (T+90)
25 of 38 declarations
About Blau Farmacêutica S.A.
BLAU FARMACÊUTICA S.A. is a Brazilian company focused on the research, development, and marketing of pharmaceutical products. It is listed on the São Paulo Stock Exchange, BVMF.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
